Category Archives: Business and Investments

Latest From Business and Investments

SBIR Reauthorization Moves Forward

SBIR Reauthorization Moves Forward

NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states that small businesses that are majority-owned by multiple venture capital operating companies are eligible to apply for (1) these SBIR grants and (2) any other NIH SBIR funding opportunities announced after January 28, 2013.  The NIH grant solicitation announcement can be found here. With this re-issuance, small businesses that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Convention Post-Con, Plus a Look Ahead

Event Signs

Last month, the biopharma community gathered for the industry’s largest event, the BIO International Convention. We hope the event was successful for everyone who attended. We know it was a busy time for folks, especially based on the numbers from the Partnering System! Here is a quick recap: BIO One-on-One Partnering Stats for BIO2013 A total of 25,537 One-on-One Partnering meetings were scheduled at the event, officially beating last year’s record! Partnering Meeting Requests increased Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both a product on the market and positive net income for FY 2012. This is about the same as the 13% reported last year, but different companies populate the list.  Unlike our last report (May 2012), when acquisitions of profitable companies Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation.  The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical promise for serious or life-threatening conditions, thereby expediting both the development and the review of these drugs. As of today, 13 designations have been granted according to a search of the BioMedTracker database (see table Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Spotlight on China

Cho

The 20th annual BIO International Convention is wrapping up in Chicago. Experts and leaders from leading global biotechnology, biologics and investment companies gathered together to discuss the opportunities and challenges in the biologics industry. A large China Food and Drug Administration (CFDA) delegation led by Deputy Commissioner Bian Zhenjia participated in a half-day session dedicated to developing a world-class therapeutic biologics industry in China. There has been a shift in recent years in the usage Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , ,